- Ciprofloxacin lactate
-
- $1.00 / 1KG
-
2026-04-30
- CAS:97867-33-9
- Min. Order: 1KG
- Purity: 98.0%,CP2000
- Supply Ability: 5ton/month
- Ciprofloxacin Lactat
-
- $0.00 / 1g
-
2026-04-30
- CAS:97867-33-9
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Ciprofloxacin lactate
-
- $1.00 / 1KG
-
2026-03-20
- CAS:97867-33-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 10 mt
|
| | Ciprofloxacin lactate Basic information |
| | Ciprofloxacin lactate Chemical Properties |
| Melting point | 255-257°C | | storage temp. | Inert atmosphere,Room Temperature | | solubility | DMSO (Slightly), Methanol (Slightly, Heated) | | form | Solid | | color | White to Off-White | | CAS DataBase Reference | 97867-33-9(CAS DataBase Reference) |
| Safety Statements | 24/25 | | HS Code | 29339900 |
| | Ciprofloxacin lactate Usage And Synthesis |
| Uses | Ciprofloxacin Lactate is an antibiotic that has been used to medicate polymer wound dressing. Ciprofloxacin Lactate has been shown to produce high and sustained serum bactericidal titers against highly susceptible bacteria. | | in vivo | Ciprofloxacin (Bay-09867) lactate (30 mg/kg; i.p.; for 24 hours; BALB/c mice) has protection against Y. pestis in murine model of pneumonic plague[3].
Ciprofloxacin (Bay-09867) lactate (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall[4].
Ciprofloxacin (Bay-09867) lactate (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall[4]. | Animal Model: | BALB/c mice[3] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneal injection; for 24 hours | | Result: | Reduced the lung bacterial load in murine model of pneumonic plague. |
| Animal Model: | C57BL/6J mice[4] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; daily, for 4 weeks | | Result: | Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity. |
| Animal Model: | C57BL/6J mice[4] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; daily, for 4 weeks | | Result: | Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall. |
| | IC 50 | Quinolone |
| | Ciprofloxacin lactate Preparation Products And Raw materials |
|